Mirodenafil-d7 dihydrochloride

Modify Date: 2024-01-09 12:16:30

Mirodenafil-d7 dihydrochloride structure	Common Name	Mirodenafil-d7 dihydrochloride
	CAS Number	1329651-11-7	Molecular Weight	611.63
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₆H₃₂D₇Cl₂N₅O₅S	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Mirodenafil-d7 dihydrochloride

Mirodenafil-d7 (SK-3530-d7) dihydrochloride is the deuterium labeled Mirodenafil dihydrochloride. Mirodenafil dihydrochloride (SK3530 dihydrochloride) is a phosphodiesterase type 5 (PDE-5) inhibitor developed for the treatment of erectile dysfunction[1][2].

Name	Mirodenafil-d7 dihydrochloride

Description	Mirodenafil-d7 (SK-3530-d7) dihydrochloride is the deuterium labeled Mirodenafil dihydrochloride. Mirodenafil dihydrochloride (SK3530 dihydrochloride) is a phosphodiesterase type 5 (PDE-5) inhibitor developed for the treatment of erectile dysfunction[1][2].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Phosphodiesterase (PDE) Research Areas >> Others
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Paick, J.S., et al., Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med, 2008. 5(11): p. 2672-80. [3]. Kim, B.H., et al., Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea. Clin Ther, 2009. 31(6): p. 1234-43. [4]. Shin, K.H., et al., The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study. Clin Ther, 2009. 31(12): p. 3009-20.

Molecular Formula	C₂₆H₃₂D₇Cl₂N₅O₅S
Molecular Weight	611.63

Mirodenafil-d7 dihydrochloride

Use of Mirodenafil-d7 dihydrochloride

Names

Mirodenafil-d7 dihydrochloride Biological Activity

Chemical & Physical Properties